CARBIOS
8.4.2020 18:02:09 CEST | Business Wire | Press release
Regulatory News:
CARBIOS (Euronext Growth Paris: ALCRB) (Paris:ALCRB), a company pioneering new bio-industrial solutions to reinvent the lifecycle of plastic and textile polymers, announces the publication of an article in the prestigious scientific journal Nature, entitled “ An engineered PET-depolymerase to break down and recycle plastic bottles” . The article is co-authored by scientists at Carbios and at the Company’s renowned academic partner, the Toulouse Biotechnology Institute 1 (TBI).
The article describes the development of a novel enzyme, which can biologically depolymerize all polyethylene terephthalate (PET) plastic waste, followed by an extremely efficient recycling into new bottles. PET is the most common thermoplastic polymer and is used to manufacture bottles, polyester clothing fibers, food containers, and various thermoformed packaging and components. Carbios’ recycling process, the first of its kind, initiates a real transition to a circular economy and can better prevent plastic pollution from harming our oceans and planet. This innovative technology also paves the way for recycling PET fibers, another major challenge in guaranteeing a clean and protected environment for future generations.
Prof. Alain Marty, Carbios’ Chief Scientific Officer and co-author of the Nature article says: "I am very proud that Nature, one of the most highly respected scientific journals in the world, has validated the quality of the research led by Carbios and TBI laboratory scientists in developing a PET recycling enzyme and a revolutionary process. The results obtained confirm the industrial and commercial potential of the Company’s proprietary process, which will be tested in 2021 in our demonstration plant in the heart of the French Chemical Valley, near Lyon."
Sophie Duquesne, INRAE Researcher: “For any researcher, seeing its work recognized by the prestigious journal Nature is a true achievement. I am very proud of the work accomplished by the researchers at TBI and Carbios, whose collaborative efforts have led to the development of a sustainable solution to the end of life of plastics.”
Dr. Saleh Jabarin, Distinguished Professor at The University of Toledo, Ohio and a member of Carbios’ Scientific Committee: “It's a real breakthrough in the recycling and manufacturing of PET. Thanks to the innovative technology developed by Carbios, the PET industry will become truly circular, which is the goal for all players in this industry, especially brand-owners, PET producers and our civilization as a whole.”
Bertrand Piccard, Founder and President of the Solar Impulse Foundation: “I am very pleased that the scientific community recognizes one of the solutions labelled by the Solar Impulse Foundation as a financially profitable solution to protect the environment. The use of such technology is as logical as it is ecological!”
Nature, the highest Impact Factor scientific journal, recognizes the ground-breaking quality of the enzymatic engineering research being done by Carbios and TBI, that is paving the way to virtuous management of plastic waste. “Carbios is the first company to successfully combine the two scientific worlds of enzymology and plastics” , as Dr. Philippe Pouletty, CEO of Truffle Capital and Co-founder of Carbios , comments.
By leveraging many years of experience with a world-renowned team, Carbios and TBI are proud to have been able to increase the degradation yield of PET waste to 90% in 10 hours, a significant upswing from the initial degradation yield of 1% after several weeks. This paradigm shift in how effectively PET can be recycled, is leading toward a future circular economy technology applicable to all PET waste, which Carbios is proud to be spearheading.
To read the article in Nature, please find the link here:
https://www.nature.com/articles/s41586-020-2149-4
About Carbios:
Carbios is a green chemistry company whose innovations help address the environmental and sustainable development challenges facing manufacturers. Since its creation in 2011 by Truffle Capital , the Company has developed, through biotechnology, two industrial processes that revolutionize the biodegradation and recycling of polymers. These world-first innovations, made possible with the support of Bpifrance (THANAPLAST™ project), enable to optimize the performance and lifecycle of plastics and textiles by exploiting the properties of highly specific enzymes.
Carbios' economic development model is based on the industrialization and commercialization of its products and/or enzymes, technologies and bioprocesses through license concessions directly or through joint ventures to major industrial players or sectors concerned by the Company's innovations. As such, Carbios created the joint venture Carbiolice in September 2016, in partnership with Limagrain Ingredients and the SPI fund operated by Bpifrance. This company, of which Carbios has majority control, will exploit the first technology licensed by Carbios by producing enzymatic granules for the production of biodegradable and biobased plastics.
Carbios benefits from the qualification "Innovative Company" of Bpifrance allowing the eligibility of the Company's securities for the investment of Mutual Funds Placement in Innovation (FCPI). For more information, please visit: www.carbios.fr
Carbios is eligible for the PEA-PME, a government program allowing French residents investing in SMEs to benefit from income tax rebates.
About Truffle Capital:
Established in 2001, Truffle Capital is a leading European Venture Capital company, specializing in breakthrough life sciences and FinTech technologies. Truffle Capital supports the creation and growth of young innovative companies capable of becoming tomorrow’s leaders. Headed by Patrick Kron, chairman, alongside cofounders and co-CEOs Philippe Pouletty, MD, and Bernard-Louis Roques, Truffle Capital has raised over €1.1 billion and has supported over 75 companies in the digital technology and life sciences sectors.
For more information: www.truffle.com – Twitter: @trufflecapital
This press release does not constitute and cannot be regarded as constituting an offer to the public, an offer to sell or a subscription offer or as a solicitation to solicit a buy or sell order in any country.
Translation for information purposes only. In case of discrepancy between the French and the English version of this press release, the French version shall prevail.
1 : A mixed research unit INSA Toulouse, INRAE, CNRS.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200408005484/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
Fastly Joins DIMPACT to Collaborate on Digital Sustainability8.7.2026 14:00:00 CEST | Press release
Fastly Brings Leading Cloud Edge Expertise to Help DIMPACT Members Understand and Optimize Digital Carbon Footprints Fastly, Inc. (NASDAQ: FSLY), a leading global edge cloud platform, today announced it has become a participant of DIMPACT, the coalition of leading organizations working to align industry changemakers and policymakers around meaningful, science-based solutions that reduce the environmental impacts of serving digital media products. As the first edge cloud platform provider to join the coalition, Fastly brings critical, real-world edge network data and infrastructure expertise and a transparent approach to emissions calculation and reporting to help major media, streaming, and publishing companies understand and optimize their digital carbon footprints. “We’re thrilled to welcome Fastly to the DIMPACT initiative. Their participation strengthens DIMPACT's ability to advance a more accurate, data-driven approach to measuring and reducing digital emissions,” said Jason Bell,
PubNub Introduces Blocks.ai: The Control Plane and Network Layer For AI Agents8.7.2026 14:00:00 CEST | Press release
Connect and control agents from everywhere, across any network and device, on the Blocks Network. PubNub introduces Blocks.ai today, a global network to connect and control agents across all agent frameworks, providers, and APIs. Blocks.ai lets developers reach their existing AI agents regardless of where they are hosted. Blocks Network supports all AI agent use cases without opening inbound ports, setting up tunnels, changing DNS, or modifying firewall rules. For more than a decade, PubNub has been the infrastructure and platform for real-time connectivity supporting billions of devices, now, PubNub delivers Blocks Network connecting the Internet of Agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708521206/en/ AI agents have become increasingly critical to businesses who want control over their models, code, and data. But once those agents are running locally or behind a firewall, making them reachable from custom
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom